RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Patient reported outcomes (pro) from ongoing phase 2 registrational trial of repotrectinib in patients with ros1-positive advanced or metastatic non-small cell lung cancer (TRIDENT-1)
Shim, A., Trone, D., Reynolds, M., Odom, D., Sherif, B., & Stopatschinskaja, S. (2022). Patient reported outcomes (pro) from ongoing phase 2 registrational trial of repotrectinib in patients with ros1-positive advanced or metastatic non-small cell lung cancer (TRIDENT-1). Value in Health, 25(12), S421. https://doi.org/10.1016/j.jval.2022.09.2093
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.
